November 27, 2024
National Cancer Institute (NCI)
The purpose of this notice of special interest (NOSI) is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries (LMICs).
Cancer is a leading cause of premature death worldwide. Predictions suggest that 30 million people will die from cancer each year by 2030, of whom 75% will be in low- and middle-income countries (LMICs). This increase may be attributed to the aging of societies, the 'epidemiologic transition' in many LMICs, the high prevalence of behaviors and exposures that increase the risk of developing cancer, as well as the socioeconomic inequalities that result in delayed diagnosis or care provision and poor-quality care in many LMIC settings.
It is estimated that 30-50% of all cancers are preventable. Specifically, one-third of global cancer deaths are attributable to behavioral risk factors, such as tobacco and alcohol use, low fruit and vegetable intake, obesity, and lack of physical activity. Tobacco use alone accounts for around 22% of the cancer mortality. Around 20-25% of cancer incidence in LMICs is attributable to chronic infections, including human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), Epstein Barr virus (EBV), human T-cell leukemia virus 1 (HTLV1), Helicobacter pylori, and other pathogens. Increasingly, in LMICs, exposure of humans to environmental and occupational risk factors, pose increasing challenges to health. Inequities in access to screening, treatment and clinical procedures persist among marginalized groups, rural populations and socio-economically disadvantaged groups. Within high-income countries, similar patterns are seen in populations experiencing health disparities and greater exposure to cancer risk factors.
A key challenge to reducing the global burden of cancer, particularly among people in LMICs and in other populations experiencing disparities, is the poor implementation of cancer prevention and control strategies that are known to work. In resource-limited settings, such interventions are under-used or have limited impact due to implementation challenges that have yet to be identified, researched, and addressed. Accelerating implementation and increasing the impact of effective evidence-based interventions, requires the generation of knowledge to guide equitable adoption, adaptation, integration, sustainability, scale-up, and spread while considering the local resource capacity, norms, values, and perspectives of stakeholders.
NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings. The research projects on which these applications will be based should be focused on dissemination and implementation research for the primary and secondary prevention of cancer in LMICs and/or in populations facing conditions of vulnerability in HICs. The projects described in grant applications must be built on evidence-based interventions (including cost-effectiveness) for the respective population groups under defined contextual circumstances. For promising interventions, a limited validation period can be envisaged. However, the core of the research activities should focus on their implementation in real-life settings.
NCI is interested in proposed studies to adapt, scale-up and sustain the implementation of these interventions in accessible, affordable, and equitable ways in order to improve the prevention and early diagnosis of cancer in real-life settings. Interventions should meet conditions and requirements of the local health and social system context and address any other contextual factors identified as possible barriers.
Research topics in the context of LMICs and other low-resource environments include, but are not limited, to the following:
NOTE: Applications proposing/describing projects involving and/or conducting research on animals are not appropriate for this funding opportunity.
For the purposes of this NOSI, LMICs are defined according to the World Bank Country and Lending Groups and are inclusive of low-income, lower-income, and upper-middle income economies.
This Notice applies to application due dates on or after October 5, 2024, and subsequent receipt dates through January 7, 2028. This NOSI expires on January 08, 2028.
Submit applications for this initiative using one of the following notices of funding opportunity announcements (NOFOs) through the expiration date of this Notice.
*Note: All the listed NOFOs are with the Simplified Review Framework (SRF) in effect. See Simplified Review Framework for NIH Research Project Grant Applications.
Activity Code | Title of NOFO | First Available Due Date |
PAR-25-144 | Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | January 05, 2025 |
PAR-25-233 | Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | January 16, 2025 |
PAR-25-143 | Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) | January 16, 2025 |
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
Note: Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research (aims) with an NCI program officer listed on this NOSI and/or on the listed funding opportunity announcements well in advance of the chosen application receipt date.
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Please direct all inquiries to the contacts in Section VII of the listed notice of funding opportunity with the following additions/substitutions:
Margarita Correa-Méndez, Ph.D., M.P.H
National Cancer Institute (NCI)
Telephone: 240-276-6871
Email: [email protected]
Gila Neta, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6785
Email: [email protected]